Until alternative promising treatment strategy has been found, individual decisions seem justified. A “wait and see” approach is not a recommendable strategy. Early GH treatment has higher chances of success than treatment attempts at the last moment. The initial degree of stunting and of bone-age retardation, GH therapy duration, time spent on conservative treatment/dialysis, pubertal delay (>2 SD), gender, and age at start of GH treatment are independent predictors of growth response to GH therapy, explaining >50 % of the overall variability .